The power of the Nanobody^® platform is such that Ablynx has the opportunity to generate development candidates across a range of therapeutic areas in just over two years. The breadth of the Nanobody^® platform and the efficiency with which leads are generated, has created partnering opportunities ranging from early-stage leads to clinical-stage licensing opportunities.

Ablynx continues to advance its own Nanobody^® research and development programmes with the goal to build a unique proprietary pipeline. Ablynx will selectively choose to partner with companies who have therapeutic expertise in relevant disease areas and a significant commitment to development and commercialisation of biologics. Ablynx has an interest to explore partnerships where alternative routes of administration could offer an advantage over existing therapies. These may include delivery devices for inhalation or subcutaneous depot.